Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting [6]

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1751-1754

  Carella, Angelo Michele ^a   Ferrara, R ^a   Orcioni, G F ^a   Pepe, G ^b   Villavecchia, G ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPIRUBICIN; FLUDARABINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADRENAL METASTASIS; ADULT; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LIVER METASTASIS; LYMPH NODE METASTASIS; MASTECTOMY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PLEURA METASTASIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING;

EID: 34848857596     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm461     Document Type: Letter

References (7)

1. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patent treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
2. Ueno NT, Rondon G, Mirza NQ et al. Allogeneic peripheral blood progenitor cells transplantation for poor risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
3. Or R, Ackerstein A, Nagler A et al. Allogeneic cell-mediated immune therapy for breast cancer after autologous stem cell transplantation: A clinical pilot study, Cytokines Cell Mol Ther 1998; 4: 1-6.
4. Bishop MR, Fowler DH, Marchigiani D et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
5. Carella AM, Beltrami G, Corsetti MT et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic, breast cancer. Lancet 2005; 366: 318-320.
6. Bregni M, Dodero A, Beccatori J et al. Non-myeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer, Blood 2002; 99(1): 4234-4236.
7. Ueno NT, Chung Cheng Y, Rondon C et al. Rapid induction of complete donor chimerism by the use of reduced intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3837.